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Background: Little is known about adult health and mortality relationships outside high-income nations, partly
because few datasets have contained biomarker data in representative populations. Our objective is to determine
the prognostic value of biomarkers with respect to total and cardiovascular mortality in an elderly population of a
middle-income country, as well as the extent to which they mediate the effects of age and sex on mortality.
Methods: This is a prospective population-based study in a nationally representative sample of elderly Costa Ricans.
Baseline interviews occurred mostly in 2005 and mortality follow-up went through December 2010. Sample size
after excluding observations with missing values: 2,313 individuals and 564 deaths. Main outcome: prospective
death rate ratios for 22 baseline biomarkers, which were estimated with hazard regression models.
Results: Biomarkers significantly predict future death above and beyond demographic and self-reported health
conditions. The studied biomarkers account for almost half of the effect of age on mortality. However, the sex gap
in mortality became several times wider after controlling for biomarkers. The most powerful predictors were simple
physical tests: handgrip strength, pulmonary peak flow, and walking speed. Three blood tests also predicted
prospective mortality: C-reactive protein (CRP), glycated hemoglobin (HbA1c), and dehydroepiandrosterone sulfate
(DHEAS). Strikingly, high blood pressure (BP) and high total cholesterol showed little or no predictive power.
Anthropometric measures also failed to show significant mortality effects.
Conclusions: This study adds to the growing evidence that blood markers for CRP, HbA1c, and DHEAS, along with
organ-specific functional reserve indicators (handgrip, walking speed, and pulmonary peak flow), are valuable tools
for identifying vulnerable elderly. The results also highlight the need to better understand an anomaly noted
previously in other settings: despite the continued medical focus on drugs for BP and cholesterol, high levels of BP
and cholesterol have little predictive value of mortality in this elderly population.
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The study of risk factors of death is central to health
metrics [1]. The effects of age and sex are routinely con-
sidered in studies of mortality. Marital status, smoking,
and obesity are also considered in many mortality
studies as shown in a recent systematic review of the lit-
erature [2]. Biomarkers are objective physical or biologic
measures of health conditions. The availability of* Correspondence: wdow@berkeley.edu
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distribution, and reproduction in any mediuminformation about biomarkers in recent population
surveys, mostly on elderly people, has opened the possi-
bility of including biomarkers in population health
metrics and in the study of mortality determinants [3].
Biomarkers are studied for their own importance, as well
as proximate factors that may help to understand the
mechanisms of action of distal factors such as education
[4] and to understand the senescence process and the
advantage of women in life expectancy [5].
The study of biomarkers as risk factors of death, espe-
cially of cardiovascular death or other severe outcomes
such as heart attacks, has a longer tradition in healthd Central Ltd. This is an Open Access article distributed under the terms of the
creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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modifiable risk factors that would allow improvements in
population health and life expectancy through changes
in behavior or in access to existing drugs or with the de-
velopment of new ones. In turn, physicians often use risk
score systems in their clinical practice to identify high-
risk individuals and to provide preventive treatment. The
paradigmatic Framingham Risk Scores identified the five
well-known coronary risk factors: age, smoking, high
blood pressure, high cholesterol, and diabetes [6]. Nu-
merous studies have validated the prediction equations
of Framingham Risk Scores in other groups [7], have
updated them with newer information [8], and have
reformulated them with new equations and additional
factors such as body mass index, waist circumference,
and C-reactive protein [9,10]. The great majority of these
studies have been based in observations of middle-age
adults from rich countries and more men than women.
A more recent generation of studies have examined the
mortality predictive value of markers of inflammation
such as C-reactive protein, interleukin-6, and fibrinogen
[11] and markers of neuroendocrine function including
adrenalin, cortisol, and dehydroepiandrosterone [12]. Sev-
eral studies have shown that biomarkers do improve pre-
diction of mortality using Receiver Operating
Characteristic (ROC) curves [13,14], although some also
question the performance and added value of traditional
blood tests and medical examination above and beyond
just age [15].
In spite of the vast literature about risk factors of
death, very little is known about health and mortality
relationships in adults in the less developed regions of
the world. This void occurs in part because until recently
few data sets have contained the necessary biomarker
data in representative populations. Most of the prior
mortality research in developing countries has concen-
trated on children and in communicable diseases,
ignoring the current predominant chronic health condi-
tions in the developing world [16]. There is thus a con-
cern about whether traditional risk factors of adult
mortality identified with data from middle-aged indivi-
duals from rich countries will hold among elderly indivi-
duals in developing countries.
The main objective of this study is to determine the
prognostic value of biomarkers with respect to total and
cardiovascular mortality in an elderly population of a
middle-income country, as well as the extent to which
they mediate the effects of age and sex on mortality.
It intends to determine the effect pattern (positive/
negative, linear/nonlinear/U-shaped) of 22 biomarkers,
measured at a baseline, on prospective death in a period
of about five years. It also aims to test whether trad-
itional coronary risk factors identified in middle aged
people from rich countries are also the major factors forelderly Costa Ricans, as well as the association with mor-
tality of newly developed biomarkers of inflammation and
neuroendocrine function. Using ROC curves the study
intends to establish the added value of the biomarkers to
predict further mortality above and beyond self-reported
health behaviors and health status at the baseline.
The context for this study is a small, ethnically and so-
cially homogeneous country with a high degree of cohe-
sion and considerable social capital. The 4.5 million
Costa Ricans have the second highest life expectancy in
the continent (Canada has the highest), higher than
richer countries like the US, Chile, or Brazil. Its public
health insurance system is almost universal, and its net-
work of primary health care outlets have been quite cost
effective at improving the health of disadvantaged groups
and erasing many health inequalities [17]. Given that eld-
erly Costa Ricans, particularly males, have been singled
out as one of the national populations with among the
lowest elderly mortality in the world [18], this study may
contribute to understanding some of the proximate
determinants of this exceptionally good health. More-
over, the Costa Rican region of Nicoya has been identi-
fied as one of a handful of places with exceptional
longevity in the world (others are the islands of Sardinia
in Italy and Okinawa in Japan), called “blue zones” [19].
This study will check if Nicoya has indeed lower mortal-
ity than the already low Costa Rican mortality and the
extent to which the Nicoya advantage is mediated by the
studied biomarkers.
Methods
Ethics statement
This observational study received ethical approval from
the Scientific and Ethical Committee of the University of
Costa Rica in session 63 of March 17, 2004. Each partici-
pant and two witnesses signed an informed consent
form. The de-identified CRELES databases are publicly
available at the National Archive of Computerized Data
on Aging (NACDA) of the University of Michigan:
http://www.icpsr.umich.edu/icpsrweb/NACDA/studies/
26681.
The CRELES data
We used data from the Costa Rican Study on Longevity
and Healthy Aging, known by its Spanish language acro-
nym CRELES. This is a longitudinal study of a nationally
representative sample of adults born before 1945 (aged
60 years and over in 2005) residing in Costa Rica, with
oversampling of the oldest old. For a nested subsample
of about 2,900 respondents, an in-depth longitudinal sur-
vey that included biomarkers was carried out, with
follow-ups through December 31, 2010 to establish sur-
vival. The baseline information on biomarkers and other
health conditions was obtained from the first wave of
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ber 2006.
The original sample was randomly selected from the
2000 census database after stratification by five-year age
groups. Sampling fractions ranged from 1.1% among
those born in 1941 to 1945 to 100% for those born in
1900 or earlier. For the in-depth longitudinal survey, the
CRELES took a systematic subsample of 60 “health
areas” (out of 102 existing in the country), covering 59%
of the Costa Rican territory. The baseline interview
yielded a response rate of 85% from the located survi-
vors. Among those interviewed, 95% provided a blood
sample, 92% collected overnight urine, and 91% had all
anthropometric measures. Twenty-four percent of the
participants required a proxy to answer the question-
naire. We also included a complementary 100% sample
of 91 quasicentenarians (aged 95 years or more) from
the area of Nicoya, which was added to the original
CRELES sample to increase the statistical power in stud-
ies of the exceptional longevity in that area. Sampling
weighting factors correct oversampling and differential
response rates by age, education, and region.
All the data and blood and urine specimens were col-
lected at the participants’ homes. After answering a 90-
minute questionnaire (including mobility tests and two
blood pressure measurements), the participants were
also instructed to collect overnight urine. Early the next
day, fasting blood samples were collected by
venipuncture: one EDTA tube of whole blood and two
serum-separating tubes with a clot activator. Details
about storage of specimens and laboratory procedures
are posted at the NACDA web site with documentation
of CRELES.
The CRELES field team was trained in a two-week ini-
tial course that included standardized anthropometric
measures. The blood and urine specimens were analyzed
in Costa Rican laboratories certified by the National
Reference Centre of Clinical Chemistry, an agency under
the Ministry of Health. In addition to routine internal re-
liability tests conducted in the laboratories, we per-
formed reliability analyses in batches of 20 to 40
specimens that were reanalyzed for each biomarker in a
different laboratory. The results of these reliability ana-
lyses, as well as some adjustments introduced to
standardize measures across the laboratories, have been
reported elsewhere [20].
The dependent variable: death
The CRELES follow up retrieved 813 deaths (564 in indi-
viduals with no missing variables) in two ways: (1)
through the computer records in the national death
registry up to December 31, 2010, and (2) during the
second and third waves of home visits. The computer
follow-up used the unique identification number (thecédula) that all Costa Ricans have. Record linkage with
the vital statistics databases, provided by the National
Statistics and Census Institute (INEC), allowed us to
identify the basic cause of death for 96% of the deceased.
Cardiovascular (CV) deaths (codes I001–I999 of the 10th
International Classification of Diseases) accounted for
35%.
Biomarkers studied and their definitions
We define biomarkers as those health indicators object-
ively measured by well-established laboratory assays on
body specimens (blood and urine in this study) or by an-
thropometrics and other standard devices, such as
dynamometers, sphygmomanometers, chronometers, or
peak flow meters. Biomarkers are thus objectively mea-
sured features of the body, in contrast to the health
conditions assessed subjectively by questions and self-
reports or by clinical examinations.
The study considered 22 biomarkers grouped in seven
dimensions of health. Within each group, some biomar-
kers may be complementary, while others may be redun-
dant. We tested these issues with the data.
Group 1. Metabolic indicators
 Glycosylated hemoglobin (HbA1c), chronic indicator
of blood sugar.
 Fasting glucose, indicator of the level of sugar at the
moment blood was drawn.
Group 2. CV biomarkers
 Diastolic blood pressure (BP), average of two
measures taken during the main interview with a
digital sphygmomanometer.
 Systolic BP, average of two measures with a digital
sphygmomanometer.
Group 3. Metabolic-lipids
 Triglycerides in fasting serum.
 Total cholesterol in fasting serum.
 High-density lipoprotein (HDL), or good cholesterol,
in fasting serum.
 Total/HDL cholesterol ratio (the two previous
markers).
 Low-density lipoprotein (LDL), or bad cholesterol
(determined with formula from total cholesterol).
Group 4. Stress hormones
 Urinary cortisol, overnight activity in the
hypothalamic-pituitary-adrenal (HPA) axis in
response to stressors.
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antagonist to HPA activity.
 Epinephrine in overnight urine, an indicator of
neuroendocrine functioning.
 Norepinephrine in overnight urine, an indicator of
neuroendocrine functioning.
Group 5. Inflammation, immune system
 C-reactive protein (CRP).
Group 6. Organ-specific functional reserve
 Creatinine clearance in overnight urine as an
indicator of kidney reserve.
 Handgrip strength measured with a dynamometer
(Creative Health Products Inc., model T-18) as an
indicator of arm muscular functioning (we took the
higher value of two measurements).
 Walking distance in 10 seconds as an indicator of leg
muscular function, derived from the chronometer
time required to walk 3 meters, imputing zero
distance to disabled participants.
 Pulmonary peak flow, an indicator of pulmonary
functioning (we took the highest value of the three
measurements obtained with a Mini-Wright meter).
Group 7. Nutrition, body shape
 Knee height, an indicator of height that is free from
the effects of aging.
 Waist circumference, an indicator of central obesity.
 Body mass index (BMI), an indicator of weight
relative to height.
 Waist/hip ratio, an indicator of body shape.
Control variables
Taking medications that affect some biomarkers:
 High BP medicine.
 Cholesterol-lowering medicine.
 Diabetes medicine.
Demographic control variables
Sex, age, and residence in the Nicoya region. All the ana-
lyses on death risk were controlled for these variables
and an interaction between age and sex.
Baseline health control variables
In some analyses, we considered the following five indi-
cators (we discarded several other indicators that did not
show meaningful associations in multiple regressions on
mortality, including other categories and indicators of
self-rated health, cognitive disability, past history ofsmoking, indicators of access to health services, and
health preventive behavior):
 Normalized disability scale computed with
information about help needed in 14 activities of
daily living (ADLs).
 Cancer diagnoses reported in the interview.
 Current smoker.
 Self-report of involuntary weight loss of 5 kg or
more in the last six months.
 Self-rated health reported as “bad” (the lowest of the
five categories).
Statistical analysis
We normalized all the biomarkers into variables with a
mean of zero and a standard deviation (SD) of one. In
this way, all their effects on mortality were on the same
scale: as the effect of increasing the biomarker in one
SD.
We modeled death with parametric proportional haz-
ard models, assuming a Gompertz distribution, which is
known to describe well human mortality at adult ages
[21]. The proportional assumption was removed by in-
cluding interactions with age, which was also the
survival-time variable. Gompertz’s assumption of linear-
ity in the logarithms of the death rates was examined
and modified accordingly by including quadratic terms
of the biomarkers in the models. We also allowed for dif-
ferential effects by sex by including sex interaction
variables.
The data were organized as a survival-time dataset,
with the date of the 60th birthday as the origin (the
birthdates in the CRELES were not self-reported, but
taken from official documents, avoiding the problem of
age exaggeration that is so pervasive among very old
people and which negatively biases the mortality esti-
mates in studies of very old ages). The date of the first
interview was the entry point into observation. The exit
date was the death date or December 31, 2010 for cen-
sored observations of survivors. In the analysis of CV
mortality, deaths by other causes are also censored
observations on the date of death. To model age prop-
erly, we split the time observed in each individual into
one-year age segments; in this way, the 2,900
participants in the CRELES became 14,100 observational
segments.
We used the STATA-11 software to estimate the death
rates and hazard regression models. All standard errors
presented are robust estimates. We did not use sampling
weights to estimate the regression models, because the
models already included the variables that defined sam-
pling weights (age, sex, and Nicoya area).
Following recent literature [13,22], we calculated the
ROC curves corresponding to the regression models
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binary classifier (our regression models) to discriminate
the true outcomes (deaths). An optimal classifier would
be one with 100% sensitivity (all deaths are classified as
deaths) and zero false positives among survivors (1 - spe-
cificity); i.e., no survivor is classified as a death. The
ROC curve shows the tradeoffs between sensitivity and
specificity. A random classifier (e.g., flipping a coin) with
no discriminatory power will follow a 45-degree line.
The area between the ROC curve and the no-
discrimination line is the Gini coefficient, broadly used
to measure the inequality in a distribution. A Gini coeffi-
cient of 1.0 corresponds to that optimal classifier that
renders 100% sensitivity and zero false positives.
Results
The mean age of the individuals in the sample was
79.7 years (10.4 SD) at the entry point (73.3 after correc-
tion for sampling weights). Because of oversampling of
the oldest old, we had more than 1,300 (46%) individuals
aged 80 years or more, which is an unusually large sam-
ple size for such old ages. The weighted proportion of
women in the sample was 53%. Twelve percent of the
participants were in the Nicoya area (8% after weighting).
The weighted mean values of the baseline health vari-
ables were 2.2 (SD= 3.0) disabilities out of 14 per person,
6% with cancer diagnoses, 10% current smokers, 9% with
involuntary weight loss, and 8% reporting bad self-rated
health.
Table 1 shows the descriptive statistics for each of the
22 biomarkers. The outliers were excluded from these
statistics and in all the analyses as indicated at the table’s
footnote. For most of the biomarkers, we had a sample
size of about 2,700 observations. The sample sizes were
substantially smaller for biomarkers from urine speci-
mens, since we have to discard all the laboratory results
for epinephrine and norepinephrine conducted in stored
urine specimens, which had degraded. We use only
results from fresh specimens, which passed our reliability
tests. The table includes information for the subsequent
interpretation of the regression results for the normal-
ized biomarkers: the mean and SD used to normalize
them, and the proportion of observations at more than 1
SD from the mean. If a biomarker followed a normal dis-
tribution, about 16% would be beyond 1 SD and 50%
above or below the mean. The distribution by waist cir-
cumference was the closest to normal.
Before using the mortality data from the CRELES, a
validity check was necessary. The age-specific death
rates from the CRELES are congruent with the series for
the entire Costa Rican population from the official life
tables for the period 2000 to 2005 [23], suggesting no
biases in the sample or errors in the identification of
deaths among the participants. Furthermore, both theCRELES and national death rates increase in logarithms
almost linearly with age, which makes it appropriate to
fit them with a Gompertz function, which also fits CV
death rates well (see Additional file 1).
Although prior research suggests that the Costa Rican
death registry is complete [18], the CRELES panel is a
golden opportunity to assess the registry’s integrity. We
were able to successfully match in the registry 99% of
deaths found in the field in the second and third waves
of interviews: only eight out of 566 deaths retrieved from
the field were not found in the registry, accounting for a
possible underregistration rate of 1.4% (95% CI: 0.6–2.8).
Moreover, as it was possible that some of these eight
missing deaths might be registered at some point in the
future or might have already been registered with wrong
identification, one can safely conclude that the Costa
Rican death registry is indeed 100% complete for ages 60
and over. In contrast, about 10% of the deaths in the
registry were not found in the field, appearing in the sec-
ond and third waves as losses of follow-up, which sug-
gests caution in relying exclusively on fieldwork to
identify deaths in this or other longitudinal studies.
In a first approach to our research problem we start
looking at just the crude effects of each isolated bio-
marker on mortality, controlling only for demographic
variables (age, sex, their interaction, and Nicoya). To es-
timate them we used a separate Gompertz regression
model for each biomarker (Table 2). The purpose of this
simplistic approach is to check the direction and size of
the effects, as well as to test the existence of nonlinear
relationships (with a quadratic term) and whether the
effects differ by age or sex as informed by the corre-
sponding interaction terms. As mentioned, the effects,
measured as rate ratios (RR), are the proportional
changes in the death rate when the biomarker increases
by 1 SD.
The following example illustrates how to read the esti-
mated effects in Table 2. A female aged 70 years with a
C-reactive protein level that is one standard deviation
above the mean has an annual death risk of 1.38 (1.42 *
0.97) compared to a woman with similar characteristics
and a CRP level equal to the mean (which is 5.6 mg/l). If
the person in this example had a CRP level 2-SD above
the mean, her relative death risk would be 1.81 (1.42 ^ 2
* 0.97 ^ 4); i.e., an 81% higher risk of dying in the coming
year. If the person of the example were 85 years old, his
death RR would be 1.69 instead. If the person were a
man, instead of a woman, the estimates would be essen-
tially the same given that the effect of being male is very
close to 1.
The biomarkers in the group “organ-specific functional
reserve” showed the strongest effects on mortality. One
SD increase in these biomarkers reduced death risk
by approximately half. There were also strong effects on
Table 1 Descriptive statistics of the 22 biomarkers investigated in the study
Proportion
Biomarker Units Mean SD ≤1SD < mean ≥ 1SD N
Metabolic hormones
Glycosylated hemoglobin (HbA1c) percent 5.76 1.13 0.01 0.69 0.09 2704
Fasting glucose mg/dl 110.64 45.39 0.01 0.70 0.09 2748
CV biomarkers
Diastolic blood pressure mmHg 83.66 12.10 0.15 0.52 0.15 2883
Systolic blood pressure mmHg 144.00 23.18 0.14 0.55 0.15 2883
Metabolic – lipids
Triglycerides mg/dl 162.84 85.27 0.10 0.62 0.13 2739
Total cholesterol mg/dl 215.54 49.42 0.14 0.54 0.15 2746
HDL cholesterol mg/dl 44.24 13.12 0.14 0.56 0.14 2743
Total/HDL cholesterol ratio ratio 5.18 1.60 0.15 0.53 0.14 2743
LDL cholesterol mg/dl 138.48 40.73 0.15 0.54 0.15 2581
Stress hormones
Urinary cortisol μg/g 26.22 24.99 0.00 0.66 0.09 2249
DHEAS μg/dl 54.06 41.72 0.10 0.62 0.15 2706
Epinephrine μg/g 7.41 10.95 0.00 0.69 0.07 1581
Norepinephrine μg/g 37.63 32.21 0.01 0.65 0.09 1631
Inflammation, immune system
CRP mg/l 5.61 6.69 0.00 0.73 0.08 2677
Organ-specific functional reserve
Creatinine clearance mg/min 74.74 30.16 0.14 0.54 0.14 2401
Handgrip strength kg 26.89 9.08 0.15 0.54 0.18 2595
Distance in 10 seconds meters 5.51 2.52 0.13 0.46 0.12 2794
Pulmonary peak flow l/min 304.66 118.65 0.15 0.57 0.17 2635
Nutrition, body size
Knee height cm 49.41 3.35 0.15 0.52 0.16 2788
Waist circumference cm 93.88 12.37 0.15 0.51 0.14 2699
BMI kg/m2 26.87 5.25 0.12 0.50 0.12 2789
Waist/hip ratio ratio 0.948 0.077 0.14 0.49 0.13 2626
The following outlier observations were dropped: triglycerides: 6 observations >700 mg/dl; LDL-C: 4 obs. >300 mg/dl; cortisol: 7 obs. >400 μg/g; DHEAS: 4 obs.
>300 μg/g; epinephrine: 2 obs. >150 μg/g; norepinephrine: 2 obs. >600 μg/g; CRP: 4 obs. >80 mg/l; creatinine: 3 obs. >250 mg/min; and waist circumference: 5
obs< 55 cm.
Statistics computed using sampling weights.
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of a 40% increase in mortality.
In the group of stress hormones, the only biomarker
that significantly predicted mortality in this sample was
DHEAS.
Body mass and shape biomarkers showed weak effects,
which differed by age. It must be noted that among indi-
viduals older than 80 years, a larger BMI or waist cir-
cumference reduced the risk of dying.
BP and lipid profile, which are biomarkers broadly
used in clinical practice, showed complex curvilinear
effects. Figure 1 translates the coefficients in Table 2 intocurves showing the effect on mortality of the full range
of these biomarker levels. The curves show that extreme
levels, both low and high, increase the risk of dying.
They also suggest that low levels of BP and cholesterol
are more risky than high levels in this population. At −2
SD, the death RRs ranged between 1.4 and 2.1 when
compared with the mean values. On the other extreme
of the curves, the death RRs associated with 2 SD above
the mean ranged between 0.8 and 1.2.
The U-shape of the curves in Figure 1 indicates that
there is an optimal level in the biomarker that minimizes
the death rate: a diastolic/systolic BP of 176/92 in
Table 2 Crude death rate ratios of normalized biomarkers
estimated with an independent hazard regression model
for each biomarker (effect of 1 SD on the death RR)
Main Square Age 80+ Male
Metabolic hormones
Glycosylated hemoglobin (HbA1c) 1.42** 0.99 0.89 0.86+
Fasting glucose 1.37** 1.00 0.84+ 0.81*
CV biomarkers
Diastolic blood pressure 0.95 1.06** 0.92 1.06
Systolic blood pressure 0.88+ 1.07** 0.89 1.11+
Metabolic – lipids
Triglycerides 0.90 1.05** 0.88 1.04
Total cholesterol 0.79** 1.07** 1.09 1.02
HDL cholesterol 0.84* 1.05* 1.15 1.00
Total/HDL cholesterol ratio 0.99 1.02** 0.89 1.01
LDL cholesterol 0.80* 1.04+ 1.08 1.02
Stress hormones
Urinary cortisol 1.00 0.99 1.15 1.12+
DHEAS 0.90 1.08** 0.93 0.87
Epinephrine 1.16 1.00 0.88 0.85
Norepinephrine 0.98 1.01 1.06 1.09
Inflammation, immune system
CRP 1.42** 0.97* 0.93 0.99
Organ-specific functional reserve
Creatinine clearance 0.72** 1.10** 1.21+ 0.97
Handgrip strength 0.41** 0.98 0.98 1.69**
Distance in 10 seconds 0.56** 1.01 1.16+ 1.08
Pulmonary peak flow 0.47** 0.97 0.97 1.39*
Nutrition, body size
Knee height 0.92 0.97 0.98 1.14
Waist circumference 1.08 1.06** 0.85+ 1.02
BMI 1.04 1.02** 0.77** 0.98
Waist/hip ratio 1.16+ 0.99 0.85+ 0.99
Significance assessed with robust estimates of standard errors: +means
significant at *p< 0.10; at **p< 0.05; and at p< 0.01.
All regression models also include control variables for sex, age (continuous),
and Nicoya.
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and of 186/96 in females and 164/89 in males at the ages
of 80 or more years (figures computed from the esti-
mates in Table 2). The optimal levels were about the
same as the sample’s average for diastolic BP (84 mmHg)
and HDL cholesterol (44 mg/dl). In contrast, for systolic
BP, total cholesterol, and triglycerides, the optimal level
was to the right (at higher levels) of the mean. The dia-
monds in Figure 1 show the cutoff levels recommended
by the American Heart Association to define metabolic
risk (>140 mmHg for systolic BP, >90 mmHg for dia-
stolic BP, >250 mg/dl for total cholesterol, >200 mg/dlfor triglycerides, and <40 mg/dl for HDL). Individuals
above these levels are considered at risk, except for
HDL, which identifies at-risk individuals as those below
the cutoff. If these curves are true causal relationships,
some conventional medical interventions would be
harmful in this population: reducing the levels of systolic
BP, total cholesterol, and, especially, triglycerides in indi-
viduals slightly above the cutoffs would increase their
risk of dying.
To what extent are the biomarkers independent from
each other? Which biomarkers overlap each other? The
correlation coefficients between pairs of biomarkers
allow a quick examination of this point (Additional file 2
summarizes the matrix of correlation coefficients show-
ing those that are 0.25 or higher). As expected, there are
several colinearities between biomarkers within the same
group: total and LDL cholesterol (r = 0.95), systolic and
diastolic BP (r = 0.72), waist circumference and BMI
(r = 0.76), and handgrip strength and spirometry
(r = 0.65). However, no meaningful correlations exist be-
tween biomarkers from different groups. The exceptions
are DHEAS, grip strength, and knee height, although
their intercorrelations seem to be a spurious result of
their association with sex.
Interestingly, the four biomarkers in the group of
organ-specific functional reserve are the only ones asso-
ciated with age (Additional file 2). Therefore, creatinine
clearance, handgrip strength, rapid walking, and pulmon-
ary peak flow might be taken by themselves as
indicators of aging. That is not the case for other
biomarkers such as blood pressure and lipid levels,
which are not clearly associated to the age of the
individuals.
An important research issue is whether some baseline
health conditions determine in part the biomarkers’
level, which would confound their crude effects on mor-
tality presented in Table 2. For example, individuals with
low levels of triglycerides could also be undernourished
or could even suffer from serious diseases, such as can-
cer, and thus their high death rates could be a conse-
quence of those conditions and not of the low levels of
triglycerides per se. To address these issues, as well as to
exclude biomarkers that are redundant, we need to esti-
mate controlled effects on mortality in multivariate re-
gression models. We could estimate a single regression
model that includes all the biomarkers and baseline
health factors in the equation. This, however, would not
be an efficient model. By including explanatory variables
that we know beforehand to be redundant to each other,
or by including variables that we know have no effect on
mortality or have many missing values, we would lose
statistical power and degrees of freedom, and thus
obtain less reliable estimates. To reduce these problems,
we decided to exclude from multivariate analyses those
11.5
2
2.5
-2 -1 0 1 2
Standard deviations from the mean
Diastolic BP (84)
Systolic BP (144)
Blood pressureDeath RR
1
1.5
2
2.5
-2 -1 0 1 2
Standard deviations from the mean
Triglycerids (163)
Total Chol. (215)
HDL Chol (44)
LipidsDeath RR
Figure 1 Crude effects of blood pressure and lipid biomarkers on death rate ratios (Costa Rican males aged 80+). Notes: The numbers
within parentheses in the legends are the mean values. The diamonds indicate the cutoff levels of metabolic risk used in clinical practice.
Although these curves are for males aged 80+ years, the curves for females and ages 60 to 79 years are similar, given that the interactions with
age and sex in Table 2 are small and nonsignificant.
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less than 2,700 observations (stress hormones, except
DHEAS, creatinine, and knee height) from the analysis.
We also dropped redundant biomarkers (fasting glucose,
diastolic BP, triglycerides, LDL cholesterol, and waist/hip
ratio), which we identified as those that do not add sig-
nificant explanation for the death rates in stepwise
regressions within each group of biomarkers. In addition,
we kept in the model only those biomarkers’ quadratic
terms and interactions with age and sex that were
significant.
Table 3 shows the multivariate estimates for the 12
remaining biomarkers. In addition to the basic demo-
graphic model, the table shows three sets of estimates:
(1) partial models that include demographic variables
and biomarkers of the same group only, (2) a full model
that estimates the effect of a biomarker net of all the
other biomarkers and the demographic controls, and (3)
a second full model that additionally controls for the po-
tentially confounding effects of baseline health variables.
To obtain comparable results from the different models,
we excluded individuals with missing values in any of the
variables. All the models were thus estimated for the
same sample of 2,313 individuals and 564 deaths.
There are no considerable changes in the magnitude
and significance of the effects of the biomarkers when
one moves from the partial to the full models (Table 3),
except for the effects of nutrition, which tend to dis-
appear and become nonsignificant. This change could be
interpreted to indicate that nutrition (body mass and
shape) has no independent effect on mortality in thispopulation. It could also be interpreted to signify that
nutrition effects are indirect or mediated by other bio-
markers, such as blood sugar or BP, and thus should not
be placed in the same equation, but modeled in a multi-
equation way.
There are also no considerable differences in the rate
ratios when we introduce the control for baseline health
in the last column in Table 3. The small decreases in the
magnitude of several RRs (movements toward 1.0) can
be interpreted as the confounding effects of baseline
health conditions on the relationships between the bio-
markers and death. Such decreases are not important,
and the effects do not change in statistical significance.
Table 3 also answers the question of whether these
biomarkers explain sex, age, and other variations in
death rates. The 9% increase in mortality per year of age
in the demographic-only model drops to 5% after the
biomarkers are introduced into the model. Therefore,
the biomarkers in the model would explain about half of
the senescence effect (more precisely, the gamma coeffi-
cient of the Gompertz mortality function estimated with
no interactions for age or sex falls from 8.21% to 4.11%
when the biomarkers are added to the demographic
model; i.e., the biomarkers explain 49.9% of the effect of
aging on mortality). The effects of disability and self-
reported health also drop by half when the biomarkers
are entered into the model. In contrast, the higher risks
of dying associated with smoking and cancer are found
to have no relation with the biomarkers. In addition, the
mortality-reducing effect of residing in Nicoya (death RR
of 0.71) changed little after controlling for biomarkers.
Table 3 Death rate ratios of normalized biomarkers
estimated with several specifications of hazard regression
models (effect of 1 SD on the death rate)
Biomarkers and control
variables
Demo-
graphic
model
Partial
models
Full
model 1
Full
model 2
Metabolic hormones
Glycosylated hemoglobin
(HbA1c)
1.23** 1.23** 1.24**
Cardiovascular biomarkers
Systolic blood pressure
(SBP)
0.85** 0.89* 0.90+
quared SBP 1.05* 1.03 1.03
SBP * Male 1.15+ 1.13 1.15+
Metabolic – lipids
Total cholesterol 0.73** 0.83** 0.85*
Squared total chol. 1.08** 1.04+ 1.03
HDL cholesterol 1.26** 1.19* 1.16*
Total/HDL cholesterol ratio 1.24** 1.19** 1.16*
Stress hormones
DHEAS 0.79** 0.83** 0.84*
Squared DHEAS 1.08** 1.05* 1.04
Inflammation, immune system
CRP 1.43** 1.27** 1.24**
Squared CRP 0.96** 0.97* 0.97+
Organ-specific functional reserve
Handgrip strength 0.55** 0.59** 0.65**
Handgrip * Male 1.62** 1.60** 1.53**
Distance in 10 seconds 0.75** 0.79** 0.90+
Pulmonary peak flow 0.71** 0.72** 0.73**
Nutrition, body size
Waist circumference 1.04 0.99 1.00
Squared waist circumference 1.06** 1.06* 1.06*
BMI * age 80+ 0.84* 0.94 0.92
Baseline health controls
Normalized disability scale 1.59** 1.27**
Cancer diagnosis 1.46** 1.51**
Involuntary weight loss 1.24* 1.17
Current smoker 1.43+ 1.50*
Bad self-reported health 1.22 1.12
Demographic controls
Male 1.65* 4.31** 3.76**
Male * Age 0.99 0.99 0.99
Nicoya 0.71* 0.66** 0.73*
Age (1 extra year) 1.09** 1.05** 1.05**
Significance assessed with robust estimates of standard errors: + means
significant at *p< 0.10; at **p< 0.05; and at p< 0.01.
Partial models include the biomarkers of the respective group AND
demographic controls. N= 2,313 individuals, 11,433 observed age segments,
and 564 deaths.
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is 1.65 times higher than that for females (Table 3). This
gap increases to 4.3 times when the model introduces
the biomarkers, signifying that the sex gap in mortality
is not caused by the biomarkers shown in the table. On
the contrary, the mystery of the excess mortality of
males deepens when one takes into account that
women usually show higher risk levels in several
biomarkers.
Figure 2 summarizes the final effects of the biomarkers
on death, as estimated by the model in the last column
of Table 3 (nutrition biomarkers are not plotted because
they are not significant). The strongest and most
straightforward predictors of death are also those basic
biomarkers that can be measured inexpensively with a
dynamometer, a chronometer, or a peak flow meter, i.e.,
the group of organ-specific functional reserve biomar-
kers. For example, the death rate for women at the low-
est end (−2 SD) of the handgrip distribution is more
than five-fold higher than that for women at the other
tail (+2 SD) of the distribution. (The discriminatory
power of the handgrip test is, however, nil for men.)
Furthermore, there are three blood tests with clear and
consistent predictive power for higher death risks: high
levels of CRP and HbA1c and low levels of DHEAS.
Individuals at the higher tail of the distribution of CRP
or HbA1c were found to have about three times higher
death rates than those at the lowest end. The effect of
DHEAS was found to be a bit smaller and in the oppos-
ite direction: reduced hormonal levels were associated
with a two-fold increase in mortality, when the extremes
of the distribution are compared.
Systolic BP appeared as a weak predictor of mortality,
and it had opposite effects depending on sex. High levels
of systolic BP predicted a slightly higher risk of dying
among men, but strikingly lower death rates among
women.
The estimated effects of total and HDL cholesterol are
complex (Figure 2). At low HDL levels, individuals with
high total cholesterol were found to be more likely to
die. In contrast, at medium or high HDL (the “good”
cholesterol) levels, the effect of total cholesterol reversed
and strikingly became a protective factor against death.
What is the joint effect of the biomarkers in predicting
mortality in this sample? The ROC curves corresponding
to the regression models presented in Table 3 show the
accuracy of these models as binary classifiers to discrim-
inate the true outcomes (deaths), as shown in Figure 3.
A Gini coefficient of 1.0 corresponds to an optimal clas-
sifier that renders 100% sensitivity and zero false posi-
tives. Our full regression model with biomarkers,
baseline health, and demographic variables demonstrated
a Gini of 0.56 as the classifier of death. This
model, for example, discriminates death with 85%
.5
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Death RR
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Figure 2 Controlled effects of normalized biomarkers on death rate ratios (elderly Costa Ricans).
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0.03 for the predicted death hazards.
The model that includes biomarkers improved the
demographics-only model (age, sex, and Nicoya) signifi-
cantly: the Gini area increased from 0.443 to 0.553, or by
25% (not shown in the Figure 3). The biomarkers also
significantly improved the model with baseline health
and demographic indicators: the Gini increased from
0.512 to 0.562, or by 10%. However, Figure 3 also puts
the results in perspective: the discrimination area added
by the biomarkers is relatively small when compared
with that achieved by the simple demographic model of
age and sex, i.e., the life table.
Cardiovascular (CV) mortality
Many biomarkers in the CRELES are markers of CV risk.
We should thus focus on their effect on CV deaths only
(with the limitation that statistical power is reduced
when we move from 564 all-cause deaths to 213 CV
deaths in our final model). We re-estimated the full re-
gression model with baseline health controls presentedin Table 3 for CV deaths, with individuals dying from
other causes taken as censored observations. Figure 4
compares the death RRs estimated with the model for
CV mortality (full, red dots) with those obtained for all-
cause mortality (hollow, blue symbols) from Table 3, full
model 2. The figure shows the effect of increasing the
biomarker from the mean to 1 SD. The dots to the left
of the RR= 1 line indicate that these biomarkers protect
against death; the dots at the right indicate an elevated
risk of death. The biomarkers in the figure are ordered
from those more protective to those more risky for CV
mortality. At the center of the figure are those neutral in
their death risk.
For most of the biomarkers, the effect on CV mortality
was found to be larger than that on all-cause deaths.
However, because of the diminished statistical power,
several of the estimated effects on CV mortality were
nonsignificant, even if they were larger than those on all-
cause mortality.
The most powerful predictors of CV death were the
organ-specific function markers: handgrip (only for
G = .562
G = .512
G = .443
0.00
0.25
0.50
0.75
1.00
0.00 0.25 0.50 0.75 1.00
Biomarkers
Baseline health
Demographic
Sensitivity
Figure 3 ROC curves for models predicting death with
estimated death hazards. G=Gini coefficient or proportional
discrimination area (between the curve and the no-discrimination
line).
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biomarkers reduced the CV deaths by 40% and 25%, re-
spectively. At the other extreme, three biomarkers sig-
nificantly increased the CV mortality by about 20%:
HbA1c, CRP, and systolic BP in males.
Among older (80+) individuals, higher BMI appeared
to be associated with low CV mortality, whereas a larger
waist circumference seemed to be related to about 20%
higher CV mortality; however, we did not have enough
statistical power to establish this effect as significant..60 .70 .83 1.0 1.2
Death RR (log scale)
HbA1c
CRP
Systolic BP males
Total Cho. Low HDL &
Waist &#
Total Chol. High HDL &
Systolic BP females &
BMI ages 80+ &#
Handgrip males &#
DHEAS &
Distance in 10 sec.
Handgrip females
All deaths CV deaths
Figure 4 Controlled effects of increasing biomarker levels by 1
SD from the mean values on death rate ratios by all causes and
CV diseases.The two traditional biomarkers of CV risk, BP and
cholesterol, showed weak and nonsignificant effects on
CV mortality, with one exception: a higher risk for males
with increased systolic BP.
Discussion
The biomarkers in this sample demonstrated significant
ability to predict future death above and beyond demo-
graphics and self-reported baseline health conditions.
However, as shown by the ROC curves, the added pre-
dictive value of the biomarkers was small when com-
pared with that of two easily observable biological traits:
age and sex. This small added value does not mean,
however, that biomarkers are not important to under-
stand mortality, but that biomarkers may act more like
proximate or mediating factors of the aging process. The
examined biomarkers explained half of the effect of age
on mortality.
In contrast with age, the sex gap in mortality became
several times wider after controlling for the biomarkers.
The mystery of the excess mortality of males deepened
when one considered that females were the ones with a
disadvantageous profile of biomarkers.
The most powerful predictors of future death, espe-
cially CV death, were three simple physical tests: hand-
grip strength for females, pulmonary peak flow, and
walking speed. Three blood tests also predicted higher
risk of mortality: CRP, HbA1c, and low DHEAS. Strik-
ingly, two groups of biomarkers, broadly accepted in
medicine as risk factors – high BP and high total choles-
terol (and triglyceride) levels – were found to have little
to no ability to predict future death (all-cause or CV) in
this dataset, with the exception of a higher CV mortality
predicted for males with high systolic BP. Furthermore,
anthropometric measures failed to show significant
effects when other biomarkers were controlled for.
The studied factors—biomarkers—are objectively mea-
sured and validated indicators, as is the endpoint defin-
ition: death. In contrast to studies of mortality in elderly
populations from developing countries, age misreporting
is not an issue because the CRELES uses only
well-documented birth dates. Underregistration of deaths
is unlikely, because the deaths are identified twice: by fol-
low-up in the field (two visits) and by computer linkage
with the death registry. Moreover, the CRELES fieldwork
demonstrated the completeness of the Costa Rican death
registry. In addition, the external validity of the study is
assured by its population-based nationally representative
sample. Because of oversampling of the oldest old, there is
a good representation of very old individuals as well as
higher statistical power. Taking biomarkers as continuous
variables (instead as binary risk factors as many epidemio-
logic studies do) and allowing for curvilinear associations
as well as effect modifications by age and sex made it
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of a normalized scale for all biomarkers made their effects
comparable. The general stability of the biomarkers’ effects
on mortality, regardless of whether other demographic
and health variables are controlled for, suggests that the
estimated effects are robust.
A weakness of the study is its limited statistical power,
especially for identifying the effects on CV mortality.
The final analysis was based only on the observation of
213 CV deaths, a small sample size that requires large
effects to reach statistical significance. Nevertheless, the
sample is large when compared with those in key previ-
ous studies in the literature from outside developed
countries, such as the SEBAS survey carried out in
Taiwan [22].
Another potential weakness is the contamination of
the sample after the first wave of visits. Although the
CRELES did not intervene to modify the health of parti-
cipants, because of ethical considerations the results of
well-established markers of CV risk were communicated
to participants with a recommendation of visiting a
physician when necessary.
A concern regarding our intent of quantifying the me-
diating effects of biomarkers in the relationship of age
and sex with mortality is that our conclusions are strictly
valid only under the assumptions that there is no con-
founding between the intermediate effects (biomarkers)
and mortality and that there is no synergism, i.e. that age
or sex does not interact with biomarkers to cause mor-
tality [24]. As with most findings from observational
studies the estimated associations can only been taken as
preliminary assessments of possible causal effects to be
checked with better designed studies.
We purposely neither included controls for socioeco-
nomic status in this study nor addressed their relation-
ship with the biomarkers. These are complex issues
addressed in other analyses of this dataset [4,17,25]. Clin-
ical use of these biomarkers for identifying high risk indi-
viduals is typically done without controlling for SES, so
similarly we want to show these straightforward models
here. In any case, we checked that our results are not
sensitive to the control for education effects by estimat-
ing the full model for all-cause and CV deaths. The in-
clusion in the regression model of the variable years of
education and its square did not change the effects of
biomarkers on mortality shown in Figure 4.
A problem in studies of elderly individuals is the poten-
tial confounding effect of earlier conditions. However, the
result that the effects of biomarkers change little when a
set of baseline health conditions is controlled for in the
models is an encouraging hint of the robustness of the
results to those hard-to-measure earlier conditions.
The simultaneous investigation of the effects of 22 bio-
markers is both a strength and weakness of the study. Itallows for a comprehensive assessment of the extent to
which biomarkers can predict mortality or can add to
what is known about the determinants of mortality at
old ages, as we did using the Gini indicator of the dis-
crimination area under the ROC curve. The downside of
this comprehensive approach is that we could not exam-
ine each of the relationships in depth, as would have
been the case in a typical epidemiologic study of one fac-
tor on one outcome.
Comparisons with other studies
Mortality rates in this sample of older Costa Ricans are
similar to that observed in the general population. Costa
Rica is known for having mortality rates at adult ages
lower than in many rich countries [18]. The life expectancy
at age 60 corresponding to the CRELES series of death
rates is 23.2 years, which is a half-year higher than that in
the US, although it is 1.7 years shorter than that in Japan
according to the Human Mortality Database [26].
The Gompertz gamma coefficient of 8.7% estimated
here with CRELES data is in the range of the Gompertz
“law” that after age 35 human mortality increases by 8%
to 14% per year, according to data from rich countries
[1]. The CRELES-based figure is, however, at the lower
end of this interval, suggesting that senescence among
elderly Costa Ricans occurs at a slower pace than in
other populations.
When Costa Rican biomarker levels are compared with
the published results from the SEBAS study carried out in
Taiwan [27], and the MacArthur, NHANES, and HRS
studies carried out in the US [4,12,25], elderly Costa
Ricans are found to be the worse off in most of their bio-
markers, a paradoxical result given the higher life expect-
ancy of adult Costa Ricans. For example, the mean systolic
BP was 144 mmHg in Costa Rica, compared with 138 in
the US and Taiwan. The prevalence of hypercholesterol-
emia (>250 mg/dL) in Costa Rica (30% of women and
15% of men) was more than double of that observed in
Taiwan and the US [4]. The only biomarkers with healthier
levels in Costa Rica were blood sugar, body mass index,
and norepinephrine when compared with the US and
blood sugar when compared with Taiwan.
This study confirms and expands the findings of the
SEBAS study of elderly Taiwanese mortality that predic-
tion is significantly improved by biomarkers and that the
standard biomarkers of CV risk have lower predictive
value than markers from the neuroendocrine and im-
mune systems [13,22,27]. Given that the SEBAS study
was limited in its small sample size (927 subjects and
162 deaths in the most recent analysis), the CRELES pro-
vides more precise estimates.
This study confirms consistent inverse associations be-
tween the measures of physical capability (such as grip
strength and walking speed) and mortality in older
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data are also consistent with those documenting a posi-
tive effect of HbA1c and CRP and an inverse effect of
DHEAS on mortality by all causes and CV conditions
[29-35]. However, there are not many studies on the
mortality effect of these three relatively new biomarkers.
In contrast, there is a large body of literature showing
the direct association of high BP and high total choles-
terol with mortality. However, the great majority of these
studies are for middle-aged individuals in developed
countries. The CRELES data analyzed in this study are
thus at odds with the paradigm that high BP and choles-
terol levels are important mortality risk factors. This is
not the first study failing to document this relationship.
For example, studies in Hawaii [36], Korea [37], the
Netherlands [38], and the US [39] did not find that low-
ering cholesterol levels reduced mortality in elderly
people. A reexamination of the data from the Framing-
ham Heart Study led to the conclusion that the direct as-
sociation between cholesterol and mortality attenuates
and even reverses with age and recommended caution
on cholesterol-lowering treatments in elderly people
[40]. The SEBAS study among elderly Taiwanese found
no evidence that high BP and high cholesterol are asso-
ciated with up to six-year prospective mortality [13,22].
In general, studies that stratify mortality effects by age
find that among older individuals, the effects of these
biomarkers are weaker or even disappear. A possibility is
that the current massive use of prescription drugs con-
ceals the effect on mortality of hypertension and high
cholesterol (among elderly Costa Ricans, 44% were found
to take antihypertension drugs and 21% were taking
cholesterol-reducing drugs, according to the CRELES).
We explored this possibility by estimating regression
models that included variables for taking these medicines
and their interactions with the biomarker levels. No sig-
nificant effects of these medicines were found. Taking
these medicines was neither a confounder nor a modifier
of the effect of the biomarkers. An exception was a
higher risk of CV death among individuals taking BP
medicine, suggesting a complex relationship that merits
an in-depth epidemiologic analysis of the data, which is
out of the scope of the present study.
Another explanation is that survivors at old ages are a
selected group of individuals among whom the effects of
traditional risk factors (usually documented with data
for middle-aged individuals) act differently or have no ef-
fect. Sorting out this survival-selection effect is not sim-
ple and is a pending research task in order to understand
health and mortality in elderly populations. Some
hints of this explanation may come from looking at the
interaction effects of age (80+ compared to 60 to
79 years) and each biomarker shown in Table 2. With
the exception of BMI, the effects of biomarkers aregenerally similar in the two age groups, which suggest
that selection effects are unlikely.
Our findings are also in line with reports that in some
special populations (individuals with advanced age, heart
failure, malignancies, AIDS, on hemodialysis, and so on)
associations between biomarkers and mortality are differ-
ent and even in the opposite direction than in the gen-
eral population. These situations have been termed
“reverse epidemiology.” It is not, however, clear whether
this reversal is a real or spurious association caused by
other conditions, such as the malnutrition-inflammation
complex syndrome [41].
From another perspective, the weak association be-
tween traditional CV biomarkers and mortality explains
at least in part the paradox that whereas adult Costa
Ricans have exceptionally high levels of life expectancy
and that their advantage mostly comes from relatively
low levels of CV mortality [18,42], they are also at higher
metabolic risk with regard to BP and cholesterol, when
compared with the elderly in countries such as Taiwan
or the US.
Conclusions
Although this study does not go as far as to establish
causal relationships that would immediately translate
into clinical practice, its results can be used to identify
individuals and populations at high risk of dying, as well
as to generate hypotheses about the possible pathways
toward higher or lower mortality levels. In addition,
these results can also be useful for checking whether the
paradigms derived from studies carried out in developed
countries, such as the Framingham study [8] hold for a
developing nation that is following a different path in its
epidemiological and nutritional transitions [17,18].
In this study, organ-specific functional reserve biomar-
kers (handgrip, walking speed, and pulmonary peak
flow), along with CRP, HbA1c, and DHEAS, have been
found to be suitable biomarkers for improving the identi-
fication of vulnerable individuals in an elderly population
of the developing world. There is now growing
evidence that these biomarkers may be important in both
clinical practice and public health surveillance. These
biomarkers are also valuable in surveys assessing health
and survival, as well as in understanding the aging
process. More research is obviously needed to under-
stand the causal mechanisms underlying these associa-
tions. Most of these biomarkers with a high predictive
value cannot be taken as causal factors or as a disease,
they are just a symptom or an indicator of a health
problem.
The lack of evidence backing well-established medical
paradigms regarding hypertension and hypercholesterol-
emia is a striking result that certainly merits further re-
search. The health expenditures for prescription drugs
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and elsewhere, and the value of these therapies for eld-
erly populations and in settings similar to Costa Rica
should be better evaluated.
Medicine needs a deeper understanding of the mean-
ing of some biomarkers in elderly populations, as well as
outside of the developed country settings, where they
have been primarily studied. Given this lack of informa-
tion, we cannot tell whether the results found for elderly
Costa Ricans is a peculiarity of this country, whose adult
population has exceptionally high life expectancy, or
whether they may be extrapolated to other adult popula-
tions in the developing world.Additional files
Additional file 1: This figure compares the age-specific mortality
rates of the CRELES sample to the national estimates in the official
life tables and shows that a Gompertz model fits them well.
Additional file 2: This figure is a correlogram showing pair-wise
correlation coefficients larger than 0.25 between the 22 biomarkers
in the study and age and sex.
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